FDA advisory panel votes against Daiichi Sankyo’s blood cancer treatment

47

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd’s treatment for adults with a type of acute myeloid leukemia.

http://feeds.reuters.com/~r/reuters/healthNews/~3/X4R11_mSy5s/fda-advisory-panel-votes-against-daiichi-sankyos-blood-cancer-treatment-idUSKCN1SK2JP